Odyssey Therapeutics, Inc. ODTX
At closeNov 11, 2026, 4:00 PM EST
After hours · Nov 11, 4:00 PM ET
- YTD
- +27.83%
- 1 year
- +27.83%
- Market cap
- 1.01B
- EPS (ttm)
- -6.33
- Shares out
- 48.07M
- Forward P/E
- -4.73
- YTD return
- +27.83%
- 1-year return
- +27.83%
- Volume
- 245.07K
- Avg volume
- 300.85K
- Open
- 19.98
- Previous close
- 20.00
- Day's range
- 19.22 – 21.21
- 52-week range
- 15.10 – 29.05
- Analysts
- Strong Buy
- Price target
- 34.67 (+65.2%)
- Earnings date
- Feb 3, 2027
5D -2.03 (-9.21%)
Key statistics
- Enterprise value
- 656.30M
- PEG ratio
- 0.00
- Price / book
- 2.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 326.00M
- Total debt
- 23.48M
- Return on equity
- 0.00%
- Short % of float
- 7.95%
- 50-day average
- 20.98
- 200-day average
- 19.71
Analyst view
Consensus: strong buy
- Target (low)
- 27.00
- Target (mean)
- 34.67
- Target (high)
- 42.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate -1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | -1.09 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -1.07 | -1.10 | -0.03 | -2.80% |
| Aug 4, 2026 | Jun 30, 2026 | -1.61 | -1.74 | -0.13 | -8.07% |
| Jun 17, 2026 | Mar 31, 2026 | -1.11 | -6.77 | -5.66 | -508.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 9, 2026 | Raymond James | init | — | Outperform |
| Aug 27, 2026 | HC Wainwright & Co. | init | — | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 18, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Jun 2, 2026 | Cantor Fitzgerald | init | — | Overweight |
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- odysseytx.com
News
Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology 
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism 
HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40 
Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate 
UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27 
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting
Your note
Sign in to keep a note on ODTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHU SHELLEY | Director | Purchase | May 10, 2026 | 11,111 |
| DIMENSION CAPITAL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2026 | 0 |
| GLICK GARY D. PH.D. | Chief Executive Officer | Conversion of Exercise of derivative security | May 10, 2026 | 415,973 |
| HAAS JASON | Chief Financial Officer | Purchase | May 7, 2026 | 62,908 |
| LEIDEN JEFFREY M | Director | Conversion of Exercise of derivative security | May 10, 2026 | 0 |
| LI NAN LN | Director | Purchase | May 10, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.98% | 6,239,237 | 130.96M | Sep 29, 2026 |
| SR One Capital Management, LP | 7.89% | 3,794,883 | 79.65M | Jun 29, 2026 |
| TPG GP A, LLC | 7.68% | 3,690,146 | 77.46M | Jun 29, 2026 |
| Lightspeed Management Company, L.L.C. | 7.51% | 3,608,443 | 75.74M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 6.24% | 3,001,198 | 63.00M | Jun 29, 2026 |
| Sanofi | 4.14% | 1,990,200 | 41.77M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.45% | 1,175,634 | 24.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.10% | 531,096 | 11.15M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.88% | 424,684 | 8.91M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.73% | 349,200 | 7.33M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.68% | 329,062 | 6.91M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.59% | 284,000 | 5.96M | Sep 29, 2026 |